TScan Therapeutics, Inc. (TCRX)

$3.7

+0.06 (+1.65%)
Rating:
Recommendation:
-
Symbol TCRX
Price $3.7
Beta 0.000
Volume Avg. 0.03M
Market Cap 88.915M
Shares () -
52 Week Range 1.6-14.71
1y Target Est -
DCF Unlevered TCRX DCF ->
DCF Levered TCRX LDCF ->
ROE -40.05% Strong Sell
ROA -40.21% Strong Sell
Operating Margin -
Debt / Equity 15.77% Neutral
P/E -
P/B 0.68 Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest TCRX news


Healthcare
Biotechnology
NASDAQ Global Market

TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.